AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28405343 — intervention group
Group type: COMPARATOR
Intervention: All Americans with DM
Number of subjects: 0
Study 28405343 — intervention group
Group type: COMPARATOR
Intervention: All Americans without DM
Number of subjects: 0
Study 28405343 — intervention group
Group type: COMPARATOR
Intervention: All Americans with/without DM
Number of subjects: 0
Study 28405344 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet and increased walking (Phase I: months 1-6)
Number of subjects: 124
Study 28405346 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 66
Study 28405346 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus insulin
Number of subjects: 66
Study 28405470 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF concentration at week 0 in patients with GCA
Number of subjects: 298
Study 28405470 — intervention group
Group type: COMPARATOR
Intervention: VEGF concentration at week 0 in controls
Number of subjects: 298
Study 28405470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of VEGF concentration at the optimal cut-off of 713 pg/mL applied to the whole cohort
Number of subjects: 298
Study 28405470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of VEGF concentration comparing biopsy-proven GCA to controls
Number of subjects: 298
Study 28405470 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry staining of biopsy from biopsy-positive GCA
Number of subjects: 298
Study 28405472 — intervention group
Group type: EXPERIMENTAL
Intervention: jSpA treatment (exact intervention not specified)
Number of subjects: 118
Study 28405473 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg QD
Number of subjects: 684
Study 28405473 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg QD
Number of subjects: 684
Study 28405473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study 28406269 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led health campaign (CLHC)
Number of subjects: 2753
Study 28406555 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and biological predictors of disease course and outcome in GBS
Number of subjects: 1400
Study 28406555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid and serial blood samples for serum and DNA
Number of subjects: 1400
Study 28406674 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (exact dosage and duration not specified)
Number of subjects: 0
Study 28406674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28406934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine-Transporter (DaT) SPECT imaging in PD patients
Number of subjects: 80
Study 28406934 — intervention group
Group type: COMPARATOR
Intervention: Dopamine-Transporter (DaT) SPECT imaging in NMC
Number of subjects: 80
Study 28406934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine-Transporter (DaT) SPECT imaging in NMC participants who later phenoconverted into PD
Number of subjects: 80
Study 28406940 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (ATIII) activity on POD1
Number of subjects: 228
Study 28406940 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII activity <61.5%
Number of subjects: 228
Study 28407138 — intervention group
Group type: EXPERIMENTAL
Intervention: ACM group
Number of subjects: 22
Study 28407138 — intervention group
Group type: EXPERIMENTAL
Intervention: After treatment of acromegaly
Number of subjects: 22
Study 28407138 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 28407139 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM)
Number of subjects: 858
Study 28407139 — intervention group
Group type: COMPARATOR
Intervention: Standard Management (SM)
Number of subjects: 858
Study 28407139 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM) after propensity score matching
Number of subjects: 858
Study 28407139 — intervention group
Group type: COMPARATOR
Intervention: Standard Management (SM) after propensity score matching
Number of subjects: 858
Study 28407216 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 6273
Study 28407492 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of anticoagulation in patients without RVT and negative D-dimer
Number of subjects: 620
Study 28407492 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation
Number of subjects: 620
Study 28408121 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV4)
Number of subjects: 1511
Study 28408121 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 1511
Study 28408140 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopause (pre-menopausal women)
Number of subjects: 76
Study 28408140 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging (post-menopausal women)
Number of subjects: 76
Study 28408140 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched men for pre-menopausal women)
Number of subjects: 76
Study 28408140 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched men for post-menopausal women)
Number of subjects: 76
Study 28408363 — intervention group
Group type: EXPERIMENTAL
Intervention: WittyFit intervention including baseline health profiling, individualized feedback, support for behavioral change, and evaluation of changes over time.
Number of subjects: 0
Study 28408363 — intervention group
Group type: EXPERIMENTAL
Intervention: WittyFit intervention for middle managers including anonymous feedback on employee problems.
Number of subjects: 0
Study 28408363 — intervention group
Group type: EXPERIMENTAL
Intervention: WittyFit intervention for executive managers providing indicators by division, location, department, age, seniority, gender, and occupational position.
Number of subjects: 0
Study 28408363 — intervention group
Group type: EXPERIMENTAL
Intervention: WittyFit intervention incorporating morbidity and well-being data.
Number of subjects: 0
Study 28408363 — intervention group
Group type: EXPERIMENTAL
Intervention: WittyFit intervention with the ability to include mortality as an outcome.
Number of subjects: 0
Study 28408434 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid lowering intervention, details not specified
Number of subjects: 0
Study 28408462 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T cells of defined formulation and dose
Number of subjects: 45
Study 28408615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, cyclophosphamide, and rituximab
Number of subjects: 21
Study 28409004 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 48
Study 28409004 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no intervention)
Number of subjects: 48
Study 28409005 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-COPD cases
Number of subjects: 38
Study 28409297 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1A2 -189_-188InsA genotype (n = 17)
Number of subjects: 30
Study 28409297 — intervention group
Group type: COMPARATOR
Intervention: SLCO1A2 -/- genotype (n = 13)
Number of subjects: 30
Study 28409328 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 63
Study 28409685 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography during Recruitment Maneuvers
Number of subjects: 0
Study 28409730 — intervention group
Group type: EXPERIMENTAL
Intervention: Activa PC+S system (Medtronic Inc.)
Number of subjects: 5
Study 28410181 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (6-month duration) via group conference calls
Number of subjects: 37
Study 28410181 — intervention group
Group type: COMPARATOR
Intervention: Weight loss maintenance phase (months 6-18) with continued group calls or mailed newsletters
Number of subjects: 37
Study 28410187 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-initiated SCP
Number of subjects: 41
Study 28410187 — intervention group
Group type: COMPARATOR
Intervention: Patient-initiated SCP
Number of subjects: 41
Study 28410187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Provider-initiated and Patient-initiated)
Number of subjects: 41
Study 28410341 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks up to 7 years
Number of subjects: 595
Study 28410341 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient CZP-ADAb-positive
Number of subjects: 595
Study 28410341 — intervention group
Group type: COMPARATOR
Intervention: CZP-ADAb-negative
Number of subjects: 595
Study 28410572 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with prophylactic antibiotics (intra-operative: 92.1%, post-operative: 96.8%)
Number of subjects: 787
Study 28410572 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with antibiotics prescribed for an average of 8.3 days for closed fractures and 9.1 days for open fractures
Number of subjects: 787
Study 28410572 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with infections present
Number of subjects: 787
Study 28410583 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality task (coincidence-timing task)
Number of subjects: 20
Study 28410813 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 84496
Study 28410816 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevnar13 vaccination
Number of subjects: 10
Study 28410816 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study 28410911 — intervention group
Group type: COMPARATOR
Intervention: nccRCC
Number of subjects: 4527
Study 28410911 — intervention group
Group type: COMPARATOR
Intervention: nccRCC (intermediate- and poor-risk)
Number of subjects: 4527
Study 28410911 — intervention group
Group type: COMPARATOR
Intervention: nccRCC (favorable risk)
Number of subjects: 4527
Study 28410911 — intervention group
Group type: COMPARATOR
Intervention: nccRCC (vascular endothelial growth factor-targeted therapy)
Number of subjects: 4527
Study 28410911 — intervention group
Group type: COMPARATOR
Intervention: nccRCC (mammalian target of rapamycin inhibitors)
Number of subjects: 4527
Study 28411249 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 30
Study 28411249 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 30
Study 28411261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular MRI (cvMRI)
Number of subjects: 103
Study 28411261 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 103
Study 28411282 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of copy-number alterations (CNAs)
Number of subjects: 446
Study 28411282 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CNAs in standard-risk group
Number of subjects: 446
Study 28411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 41
Study 28411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 41
Study 28411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum buffet meal
Number of subjects: 41
Study 28411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture display test
Number of subjects: 41
Study 28412293 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir (300mg glecaprevir plus 120mg pibrentasvir) for 8 weeks in genotype 1-, 2-, or 3-infected patients
Number of subjects: 449
Study 28412293 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir for 12 weeks
Number of subjects: 449
Study 28412293 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir for 8 weeks
Number of subjects: 449
Study 28412293 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir
Number of subjects: 449
Study 28413427 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant) administered concurrently with TIV
Number of subjects: 220
Study 28413427 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant)
Number of subjects: 220
Study 28413427 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV F nanoparticle vaccine (adjuvanted)
Number of subjects: 220
Study 28413427 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV F nanoparticle vaccine co-administered with TIV
Number of subjects: 220
Study 28413427 — intervention group
Group type: COMPARATOR
Intervention: TIV
Number of subjects: 220
Study 28413832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 28413832 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 28414029 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPTURE-S with selective use of PEF
Number of subjects: 30
Study 28414819 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 2233
Study 28414819 — intervention group
Group type: EXPERIMENTAL
Intervention: PG
Number of subjects: 2233
Study 28414819 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG
Number of subjects: 2233
Study 28414819 — intervention group
Group type: COMPARATOR
Intervention: CAVI and baPWV
Number of subjects: 2233
Study 28414894 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAT Cancer physical activity intervention
Number of subjects: 0
Study 28415102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuin-A level ≤0.53 g/L
Number of subjects: 296
Study 28415102 — intervention group
Group type: COMPARATOR
Intervention: Fetuin-A level >0.53 g/L
Number of subjects: 296
Study 28415993 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving To Business (MTB) intervention
Number of subjects: 396
Study 28416015 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation therapy (AT)
Number of subjects: 2180
Study 28416015 — intervention group
Group type: COMPARATOR
Intervention: No augmentation therapy (AT)
Number of subjects: 2180
Study 28416015 — intervention group
Group type: COMPARATOR
Intervention: COPD patients without AATD
Number of subjects: 2180
Study 28416221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, plus dasabuvir 250 mg for 8 weeks
Number of subjects: 166
Study 28416221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin for 8 weeks
Number of subjects: 166
Study 28416496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including a 3-week residential programme combining high exercise volume (15-20 hours/week), restrictive diet (-500 kcal/day), and education.
Number of subjects: 29
Study 28416559 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-based catheter lock solution (15 or 30 μg/ml of nitroglycerin in combination with 4% sodium citrate and 22% ethanol)
Number of subjects: 60
Study 28416559 — intervention group
Group type: COMPARATOR
Intervention: Standard care (saline or heparin flush)
Number of subjects: 60
Study 28416559 — intervention group
Group type: COMPARATOR
Intervention: Institutional rate
Number of subjects: 60
Study 28416813 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol secretion
Number of subjects: 0
Study 28416813 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) Val
Number of subjects: 0
Study 28417002 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa Stages of Change Questionnaire (ANSOCQ)
Number of subjects: 0
Study 28417284 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib 70 mg QD
Number of subjects: 49
Study 28417284 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib 50 mg BID
Number of subjects: 49
Study 28417284 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib 60 mg QD (MTD)
Number of subjects: 49
Study 28417284 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib 40 mg BID (MTD)
Number of subjects: 49
Study 28417284 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib (all doses)
Number of subjects: 49
Study 28417284 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib with food
Number of subjects: 49
Study 28417296 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 inhibitors (saxagliptin)
Number of subjects: 0
Study 28417296 — intervention group
Group type: COMPARATOR
Intervention: DPP4 inhibitors
Number of subjects: 0
Study 28417532 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-naïve T2D patients
Number of subjects: 0
Study 28417532 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated T2D patients
Number of subjects: 0
Study 28417532 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 0
Study 28417532 — intervention group
Group type: EXPERIMENTAL
Intervention: All populations
Number of subjects: 0
Study 28419213 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV PCR in saliva
Number of subjects: 11715
Study 28419213 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary maternal infection
Number of subjects: 11715
Study 28419213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprimary maternal infection
Number of subjects: 11715
Study 28419213 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegative women before pregnancy
Number of subjects: 11715
Study 28419237 — intervention group
Group type: EXPERIMENTAL
Intervention: FAT score ≥2
Number of subjects: 183
Study 28419237 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard quantification method for scAT fibrosis
Number of subjects: 183
Study 28419237 — intervention group
Group type: EXPERIMENTAL
Intervention: FAT score interobserver agreement
Number of subjects: 183
Study 28419383 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA
Number of subjects: 549
Study 28419383 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS
Number of subjects: 549
Study 28419383 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 549
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) during hospitalization for STEMI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) during hospitalization for NSTEMI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) during hospitalization for UA
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at discharge for STEMI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at discharge for NSTEMI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at discharge for UA
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT at 12 months for STEMI patients managed by PCI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT at 12 months for STEMI patients conservatively treated
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT at 12 months for NSTEMI patients managed by PCI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT at 12 months for NSTEMI patients conservatively treated
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 1 year for STEMI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 2 years for STEMI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 1 year for NSTEMI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 2 years for NSTEMI
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 12 months for UA
Number of subjects: 600
Study 28420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 24 months for UA
Number of subjects: 600
Study 28420280 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg or 6 mg once daily for 8 weeks (induction study)
Number of subjects: 108
Study 28420280 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg once daily for 12 weeks (maintenance study)
Number of subjects: 108
Study 28420329 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced US using perfluorobutane
Number of subjects: 523
Study 28420329 — intervention group
Group type: COMPARATOR
Intervention: Conventional B-mode US
Number of subjects: 523
Study 28420362 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop, allostatic neurotechnology
Number of subjects: 19
Study 28420419 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Your New Normal program (automated telephone symptom management intervention)
Number of subjects: 600
Study 28420419 — intervention group
Group type: COMPARATOR
Intervention: Usual care enhanced with a non-tailored newsletter about symptom management
Number of subjects: 600
Study 28420419 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Your New Normal program
Number of subjects: 600
Study 28420429 — intervention group
Group type: EXPERIMENTAL
Intervention: DEPTOR knockdown in H929 and MM1S cell lines
Number of subjects: 0
Study 28420429 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of DEPTOR protein expression in myeloma patients
Number of subjects: 0
Study 28420664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron administration according to hospital's preoperative pathway
Number of subjects: 0
Study 28420664 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28420721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide delivered intravenously
Number of subjects: 0
Study 28421334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for at least 8 weeks
Number of subjects: 889